Cogstate Ltd · ASX:CGS
Cogstate — Non-Deal Roadshow (January 2017)
21 slides from Cogstate's roadshow presentation, Jan 30, 2017
Slide 1: ASX Announcement: Company Update
ASX ANNOUNCEMENT 30 JANUARY 2017 For personal use only COMPANY UPDATE Cogstate Ltd (ASX.CGS), a world-class cognitive science, technology and services company, is pleased to release a company update presentation, which is attached to this announcement. The presentation outlines Cogstate’s compelling
Slide 2: Investor Presentation January 2017
For personal use only Investor Presentation January 2017 © 2016 Cogstate Ltd. All rights reserved.
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS A world-class cognitive science, technology and services company focused on For personal use only optimising and monetising the measure of cognition (Refer to slides) § Cogstate is at a major inflection point as it accelerates the commercialisation 4 of 15+ years of world-class
Slide 4: Corporate Overview
CORPORATE OVERVIEW Strong conviction from long-term shareholders has enabled Cogstate to develop a For personal use only unique technology platform, extensive validation and expanding supporting services Highly credentialed and well aligned Board and Trading information management team holding >40%
Slide 5: Cogstate Share Price Performance
COGSTATE SHARE PRICE PERFORMANCE Recent share price momentum is reflective of continued sales, revenue and For personal use only earnings growth as commercialisation efforts accelerate Historical share price performance (A$) Commercialisation gaining momentum (last 18 months) 1.60 1.60 2Q17 Product
Slide 6: 1H17 Financial Highlights
1H17 FINANCIAL HIGHLIGHTS 1H17 was a record half year, with strong momentum expected to continue in 2H17 For personal use only Sales contracts executed Contracted future revenues US$23.0m US$31.7m 1H16: US$17.1m 30-Jun-16: US$25.2m +35% Record half of new sales contracts signed +26% Strong contracte
Slide 7: The Leader in Digital Brain Health Assessments
THE LEADER IN DIGITAL BRAIN HEALTH ASSESSMENTS WE BELIEVE THAT BRAIN HEALTH IS PROFOUNDLY IMPORTANT AND SHOULD BE EASIER TO MEASURE. THAT’S WHY WE APPLY OUR SCIENTIFIC EXPERTISE, SENSITIVE MEASURES AND For personal use only FLEXIBLE TECHNOLOGY TO SIMPLIFY THE ASSESSMENT OF COGNITION. A unique combin
Slide 8: Validated and Scalable Technology Platform
VALIDATED AND SCALABLE TECHNOLOGY PLATFORM 15+ years of investment in Cogstate’s scalable technology platform underpins For personal use only accelerating commercial success and provides foundation for further growth Validated approach Access to data Built for growth Technology is clinically and Acc
Slide 9: Senior Executive Appointments
SENIOR EXECUTIVE APPOINTMENTS To further accelerate revenue growth in Clinical Trials and Healthcare businesses For personal use only GEORGE HUNNEWELL FRANK CHENG COO & President of Clinical Trials President of Healthcare Appointed November 2016 (US based) Appointed November 2016 (US based) § 25 yea
Slide 10: Clinical Trials Overview
CLINICAL TRIALS OVERVIEW Cogstate is steadily expanding beyond its core Alzheimer’s Disease foundation For personal use only Alzheimer’s disease Oncology >60 other indications § 40% to 60% of new contracts § 5% to 20% of new contracts § 20% to 50% of new contracts § Initial commercial focus from § C
Slide 11: Market Opportunity in Clinical Trials
MARKET OPPORTUNITY IN CLINICAL TRIALS ~$800m annual opportunity for cognition assessment in clinical trials For personal use only Three key applications in efficacy, safety and screening Clinical trials context worth ~US800m annually in clinical trials Large and growing clinical research Average mar
Slide 12: Strong Execution to Date
STRONG EXECUTION TO DATE Rapid growth in sales and strong contracted revenue demonstrates the value of For personal use only Cogstate’s solution and offering Sales contracts executed vs. recognised revenue (US$m) 2H17 sales contract Key go-to-market steps in and revenue potential 28.5 Clinical Trial
Slide 13: World Class Customer Base
WORLD CLASS CUSTOMER BASE Cogstate is a key partner to the world’s leading pharmaceutical companies For personal use only Cogstate currently works with 9 of the top 10 76% of new clinical trials contracts pharmaceutical companies (ranked by R&D Spend) are signed by repeat clients Why do clients cont
Slide 14: Rapid Growth in Contracted Revenue Pipeline
RAPID GROWTH IN CONTRACTED REVENUE PIPELINE Long term contracted revenues de-risks Cogstate’s investment proposition For personal use only Growth in contracted revenue pipeline (US$m) +76% § The long term nature of Cogstate’s contracts provides forward sight of revenue and allows us to optimise reso
Slide 15: Clinical Trials Strategic Objectives
CLINICAL TRIALS STRATEGIC OBJECTIVES Leverage strong initial market traction to rapidly grow the business For personal use only Expansion into Europe and Almost entirely US based today – significant Rest of the World potential in Europe / RoW Establish strategic partnerships Fully leverage Cogstate’
Slide 16: Healthcare Market Opportunity
HEALTHCARE MARKET OPPORTUNITY Potential for >25m cognition tests per year in US alone For personal use only SETTING HOSPITALS HOSPITAL PHYSICIAN OFFICE CONSUMER HEALTH CONSUMER HEALTH COGNITION § Pre/post surgery assessment § Alzheimer’s screening TESTING § ICU patient assessment § Drug effect monit
Slide 17: Cogstate Has a Superior Solution for Healthcare
COGSTATE HAS A SUPERIOR SOLUTION FOR HEALTHCARE Potential to capture market leadership with a web-based, regulatory cleared For personal use only medical device designed for the measurement of cognition in healthcare Opportunity to address key gaps in detection and CognigramTM combines validated tes
Slide 18: Healthcare Strategy and Roadmap
HEALTHCARE STRATEGY AND ROADMAP Initial investment will focus on creating US market demand to facilitate For personal use only partnerships for broader commercialisation Strategic Priorities Launch Partnership Growth 1) Regulatory Clearance Secure US regulatory Launch offering and drive Explore and
Slide 19: Key Operational Milestones for Healthcare
KEY OPERATIONAL MILESTONES FOR HEALTHCARE Growth to be managed against a clear set of operational and financial milestones For personal use only Key goals for next 18 months § Complete regulatory submissions § Demonstrate potential for and secure regulatory clearances adoption in professional settin
Slide 20: Key Future Developments
KEY FUTURE DEVELOPMENTS Cogstate is well placed to capitalise on exciting long-term growth opportunities For personal use only FY 2017 FY 2018 • Expansion into Europe and Rest of • Continued investment in the World commercial team and R&D Clinical Trials • Establishment of strategic • Develop and li
Slide 21: Cogstate
COGSTATE Cognition disorders Alzh ej mer's disea S@ Heart failure Major depressive disorder muttipte sclerosis (Ms) Hepatitis C Parkinson's disease Diabetic peripheral neuropathy Mild cognitive impairment Insomnia Sch izo p h ren ia Overactive bladder Stroke Obsessive compulsive disorder Alcohol Tox